Sickle cell disease lags behind other neglected diseases in terms of R&D. Adding sickle cell disease to the FDA’s priority review voucher list of neglected tropical diseases may incentivize drug companies to increase their investment in R&D.
Adding Sickle Cell Disease To FDA’s Priority Review Voucher List Of Neglected Tropical Diseases
